A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflectra ®) For The Treatment of Ankylosing Spondylitis In Nine European Countries
Abstract
Authors
F Rencz M Péntek L Gulacsi P Baji
F Rencz M Péntek L Gulacsi P Baji
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now